Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
User is using a topical solution with .1% finasteride, 6% minoxidil, and .0125% tretinoin for hair loss, along with a .25 derma roller once a week. They are concerned about the necessity and potential side effects of using the derma roller.
The user is experiencing scalp irritation from a compounded treatment of finasteride, minoxidil, and tretinoin. They are considering switching to a non-alcohol, propylene glycol-free formula with a lower tretinoin percentage to reduce irritation.
The conversation is about using tretinoin to enhance the effects of minoxidil for hair loss, with suggestions to switch from finasteride to dutasteride or use RU58841 for better results. Concerns about tretinoin causing dry scalp and its potential impact on hair loss progression are also discussed.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
Serevelle is being considered for hair loss due to menopause, but its effectiveness is unclear. Minoxidil and hormone management are suggested alternatives.
People are discussing using tretinoin gel with minoxidil to improve hair growth, especially for those who didn't respond to minoxidil alone. They apply a mix of tretinoin gel and minoxidil to the scalp, which is said to be more effective than minoxidil by itself.
A 28-year-old male experienced hair regrowth using a topical spray containing minoxidil, finasteride, and tretinoin, along with occasional microneedling, after stopping oral finasteride due to side effects. He is pleased with the progress after three months and plans to continue using the spray.
Oral minoxidil and finasteride are the main treatments for hair loss, with microneedling as an additional method. Tretinoin gel is not necessary with oral minoxidil but can be used for skincare.
A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.
The user has been using oral finasteride and topical minoxidil for years and recently started 2.5 mg oral minoxidil, with no significant regrowth observed yet. They are considering adding tretinoin cream to their regimen but are concerned about potential shedding.
JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.
The post and conversation are about a hair loss treatment stack without finasteride or dutasteride. The suggested treatments include Alfatradiol, Koshine826, Ketoconazole lotion, Minoxidil, microneedling, Tretinoin, and Stemoxydine.
Deoxyribose sugar gel is discussed as a potential hair loss treatment, but it lacks human trials and credible evidence. Users express skepticism and humor about its effectiveness compared to established treatments like minoxidil and finasteride.
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.
The user uses rosemary oil, finasteride, ketoconazole, Minoxidil, and Anagenics RU58841 for hair loss treatment. They hope rosemary oil will improve scalp health.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
A user has been losing hair for two and a half years after a tropical trip and illness. A dermatologist prescribed betamethasone valerate 0.1% lotion, but the user is unsure if it's safe or effective for general hair loss.
1% finasteride is considered too high, with most people using 0.1% or 0.3% topically. Combining it with 0.1% tretinoin is aggressive and may cause skin irritation.
A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.
The conversation humorously discusses various hair loss treatments and alternatives, including finasteride, minoxidil, and rosemary oil, with some users joking about wigs and unconventional items like roadkill. One user mentions using oral finasteride and minoxidil, topical rosemary oil, and microneedling.
Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.